EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Global prevalence of claudin 18 isoform 2 in tumors of patients with locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma

Kohei Shitara, Rui-Hua Xu, Jaffer A Ajani, Diarmuid Moran, Abraham Guerrero, Ran Li, Janet Pavese, Maria Matsangou, Pranob Bhattacharya, Yoko Ueno, Xuewei Wang, Manish A Shah iD

Gastric Cancer · 2024-09 · 27 (5) · 1058-1068

DOI: 10.1007/s10120-024-01518-1 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Gastric Cancer, online erschienen am 02.07.2024. Verfasst von Kohei Shitara und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastrointestinal Oncology, National Cancer Center Hospital East, Kashiwa City, Chiba, Japan. Hauptthemen laut MEDLINE: Adenocarcinoma, Claudins, Esophageal Neoplasms, Esophagogastric Junction. Die Arbeit wurde bisher 98-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Astellas Pharma Inc..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Limited data exist for global prevalence of claudin 18 isoform 2 (CLDN18.2) positivity and association of CLDN18.2 status with clinical and tumor characteristics in patients with locally advanced (LA) unresectable or metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinoma. We report prevalence of CLDN18.2 positivity (phase 3; SPOTLIGHT, NCT03504397; GLOW, NCT03653507) and concordance of CLDN18.2 status between a subset of pair-matched tumor samples (phase 2, ILUSTRO, NCT03505320; phase 1, NCT03528629) from clinical studies of zolbetuximab.

Methods

Tumor samples from patients with LA unresectable or mG/GEJ adenocarcinoma were tested for CLDN18.2 status by immunohistochemistry. Human epidermal growth factor receptor 2 (HER2) expression was tested per central or local assessment.

Results

Across SPOTLIGHT and GLOW, the prevalence of CLDN18.2 positivity (≥ 75% of tumor cells demonstrating moderate-to-strong membranous CLDN18 staining) was 38.4%. Prevalence was similar in gastric versus GEJ adenocarcinoma samples and regardless of collection method (biopsy versus resection) or collection site (primary versus metastatic). CLDN18.2 positivity was most prevalent in patients with diffuse-type tumors. In ILUSTRO and the phase 1 study, concordance of CLDN18.2 positivity was 61.1% between archival (i.e., any time before treatment) and baseline (i.e., ≤ 3 months before first treatment) samples, and concordance of any CLDN18 staining (≥ 1% of tumor cells demonstrating moderate-to-strong membranous CLDN18 staining) was 88.9%.

Conclusions

CLDN18.2 was a highly prevalent biomarker in patients with HER2-negative, LA unresectable or mG/GEJ adenocarcinoma. CLDN18.2 positivity remained relatively stable over time in many patients. Biomarker testing for CLDN18.2 should be considered in standard clinical practice in these patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AdenocarcinomaClaudinsEsophageal NeoplasmsEsophagogastric JunctionStomach NeoplasmsAdultAgedFemaleHumansMaleMiddle AgedBiomarkers, TumorPrevalenceProtein IsoformsClinical Trials as Topic

Stichwörter der Autor:innen

BiomarkersClaudin 18 isoform 2 prevalenceGastric cancerGastroesophageal cancerZolbetuximab

Substanzen

Biomarkers, TumorClaudinsCLDN18 protein, humanProtein Isoforms

Autor:innen und Institutionen

  • Department of Gastrointestinal Oncology, National Cancer Center Hospital East, Kashiwa City, Chiba, Japan.
  • Department of Medical Oncology, Sun Yat-Sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China.
  • Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine, The University of Texas, MD Anderson Cancer Center, Houston, TX, USA.
  • Astellas Pharma Global Development, Inc., Northbrook, IL, USA.
  • Astellas Pharma Inc., Tokyo, Japan.
  • Division of Hematology and Medical Oncology, Weill Cornell Medical College, New York City, NY, USA. mas9313@med.cornell.edu.

ORCID-Profile: Manish A Shah

Förderung

  • Astellas Pharma Inc.

Zitieren

APA

Shitara, K., Xu, R. H., Ajani, J. A., Moran, D., Guerrero, A., Li, R., Pavese, J., Matsangou, M., Bhattacharya, P., Ueno, Y., Wang, X., & Shah, M. A. (2024). Global prevalence of claudin 18 isoform 2 in tumors of patients with locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma. Gastric Cancer, 27(5), 1058-1068. https://doi.org/10.1007/s10120-024-01518-1

Vancouver

Shitara K, Xu RH, Ajani JA, Moran D, Guerrero A, Li R, et al. Global prevalence of claudin 18 isoform 2 in tumors of patients with locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma. Gastric Cancer. 2024;27(5):1058-1068. doi:10.1007/s10120-024-01518-1

BibTeX
@article{Shitara2024,
  author = {Shitara, Kohei and Xu, Rui-Hua and Ajani, Jaffer A and Moran, Diarmuid and Guerrero, Abraham and Li, Ran and Pavese, Janet and Matsangou, Maria and Bhattacharya, Pranob and Ueno, Yoko and Wang, Xuewei and Shah, Manish A},
  title = {Global prevalence of claudin 18 isoform 2 in tumors of patients with locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma},
  journal = {Gastric Cancer},
  year = {2024},
  volume = {27},
  number = {5},
  pages = {1058--1068},
  doi = {10.1007/s10120-024-01518-1}
}
Kostenlos starten →